AWS
NAGE

Atria Wealth Solutions’s Niagen Bioscience NAGE Stock Holding History

Atria Wealth Solutions’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$139K Buy
10,950
+100
+0.9% +$987 ﹤0.01% 1417
2025
Q1 		$74.9K Buy
+10,850
New +$68.2K ﹤0.01% 1809

Other funds holding NAGE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
TCM
Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Atria Wealth Solutions's NAGE Position: Q2 2025 in Review

Atria Wealth Solutions increased its Niagen Bioscience (NAGE) stake by 0.92% in Q2 2025, buying an estimated $987 and bringing the position to 10,950 shares worth $139K. The position accounts for ﹤0.01% of the portfolio, ranked #1417.

Atria Wealth Solutions first reported a position in NAGE in Q1 2025 and has held it in 2 quarters since. 155 funds tracked by Wall St. Rank hold NAGE as of Q2 2025.

  • Atria Wealth Solutions held 10,950 shares of Niagen Bioscience worth $139K as of Q2 2025.
  • Atria Wealth Solutions bought 100 Niagen Bioscience shares in Q2 2025, an estimated $987.
  • Niagen Bioscience made up ﹤0.01% of Atria Wealth Solutions's portfolio in Q2 2025, its #1417 holding.
  • Atria Wealth Solutions first reported a position in Niagen Bioscience in Q1 2025 and has held it in 2 quarters since.
  • 155 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2025.

Based on Atria Wealth Solutions's 13F filing for Q2 2025, filed 25 Jul 2025.